Wet age-related macular degeneration is the leading cause of blindness in the older U.S. population. It is estimated that there are about 1.6 million people with wet AMD in the U.S. There are several approved treatments for wet AMD, mostly in the form of anti-VEGF eye injections. These include Roche's Lucentis and Vabysmo; Regeneron's Eylea and Eylea HD; and Novartis' Beovu. There are also approved biosimilar drugs, such as Byooviz from Samsung Bioepis and Biogen, and Cimerli from Coherus BioSciences, for wet AMD.
The stock we are bringing to your attention today is that of Ocular Therapeutix Inc. (OCUL), which is also developing a treatment for wet AMD.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.